Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Author Affiliations

₁Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT₂Leipzig University Hospital, Leipzig, Germany₃Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY₄Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Harvard University, Boston, MA₅Service d’hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris) and Université de Paris-Cité, Paris, France₆Division of Hematology, Department of Internal Medicine, James Cancer Center, The Ohio State University, Columbus, OH₇St James’s Institute of Oncology, Leeds, United Kingdom₈Division of Oncology and Malignant Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada₉Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA₁₀Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH₁₁Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX₁₂Hematology Department, University Hospital of Salamanca, Institute for Biomedical Research of Salamanca, Universidad de Salamanca, Salamanca, Spain₁₃Department of Tumor Immunology, Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands₁₄Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD₁₅Data Center and Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy₁₆Klinik für Hämatologie, Onkologie und klinische Immunologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany₁₇St Mary’s Hospital, Düsseldorf, Germany₁₈Roswell Park Comprehensive Cancer Center, Buffalo, NY₁₉Department of Pathology, Massachusetts General Hospital, Boston, MA₂₀Karolinska Institutet, Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska University Hospital, Stockholm, Sweden₂₁Sanatorio Universitario Sagrado Corazón, Ciudad Autónoma de Buenos Aires, Argentina₂₂Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL₂₃Department of Haematological Medicine, King’s College Hospital, National Institute of Health Research/Wellcome King’s Clinical Research Facility and King’s College London, London, United Kingdom₂₄Department of Hematology, University of Pavia & IRCCS S. Matteo Hospital Foundation, Pavia, Italy₂₅Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan₂₆Leukemia Program, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL₂₇MDS Unit, AOUC, University of Florence, Florence, Italy₂₈Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain, Health Research Institute La Fe, Valencia, Spain; and CIBERONC, Instituto de Salud Carlos III, Madrid, Spain₂₉Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil₃₀Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria₃₁Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Medical Center, Amsterdam Cancer Center, Amsterdam, The Netherlands₃₂Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia₃₃Division of Hematology, Sylvester Comprehensive Cancer Center, Miami Miller School of Medicine, University of Miami, Miami, FL